Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention

Launched by SAMSUNG MEDICAL CENTER · Mar 7, 2023

Keywords

ClinConnect Summary

Intervention

1. Control group (dual therapy) study drug (placebo): normal saline 150ml Dexamethasone 5 mg palonosetron 0.075 mg,
2. Experimental group (triple therapy) Study Drug (Fosaprepitant): resolved in normal saline 150mL Dexamethasone, Palonosetron 0.075mg,

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patients undergoing laparoscopic gynecological surgery.
• • Adults between the ages of 18 and 50
• • American Society of Anesthesiologists Physical Status (ASA physical status I, II
• Exclusion Criteria:
• • American Association of Anesthesiologists physical standards (ASA physical status III or higher)
• • Children under the age of 19
• • Adults over 49 years of age
• • Diabetes Mellitus
• • Pregnant or lactating women
• • Patients with a history of allergy or contraindications for use of the study drug
• • Patients who did not understand this study or expressed their refusal.
• • Patients with a history of serious psychologic disease that may affect the patient evaluation
• • Patients taking serotonergic drugs